CN1666745A - Drug composition for treating osteoporosis - Google Patents
Drug composition for treating osteoporosis Download PDFInfo
- Publication number
- CN1666745A CN1666745A CN 200410008458 CN200410008458A CN1666745A CN 1666745 A CN1666745 A CN 1666745A CN 200410008458 CN200410008458 CN 200410008458 CN 200410008458 A CN200410008458 A CN 200410008458A CN 1666745 A CN1666745 A CN 1666745A
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- deals
- longistylin
- osteoporosis
- pinostrobin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a new drug compound for treating osteoporosis, comprising following active components in the proportion of weight fractions: cajanus cajan (L. ) Millsp is 95-105 deals, cajanus cajan (L. ) Millsp A3 is 13 deals, cajanus cajan (L. ) Millsp C2 is 7 deals, pinostrobin is 55-65 deals, vitexin is 55-65 deals, naringenin dimethyl ether is 2-7 deals, and salicylic acid is 15-25 deals. Said inventive drug compound can be processed to any drug form of pharmacology by adding different excipients. And the invention has the functions of inducing bone formation, preventing bone absorption, and treatment for osteoporosis of climacteric (spaying) women, the elderly, and the ones induced by hormone. The invention also can diminish inflammation for treating trauma, burn, and aphtae.
Description
Technical field
The present invention relates to a kind of pharmaceutical composition that is used for the treatment of osteoporosis, relating in particular to a kind of is pharmaceutical composition of forming of feedstock production and preparation method thereof with the active component that is extracted in the plant.
Background technology
Osteoporosis is a kind of physiological degenerative disease relevant with endocrine function, the patient presents pathological changes such as the osseous tissue microstructure is impaired, sclerotin attenuation, the increase of bone fragility, the clinical onset rate is very high in elderly population, climacteric women, brings very big misery to the patient.
At present, the clinical treatment osteoporosis mainly adopts calcium preparation and estrogens two class medicines, this two classes medicine, and the former clinical efficacy is not ideal enough, and the latter takes for a long time and has obvious toxic and side effects.
Summary of the invention
The purpose of this invention is to provide a kind of pharmaceutical composition that has no side effect that can effectively treat osteoporosis.
The objective of the invention is to realize by following approach:
Pharmaceutical composition of the present invention contains the active component of following weight proportioning:
Cajanin 95～105, Longistylin A 3～13, Longistylin C 2～7, pinostrobin 55～65, vitexin 55～65, naringenin dimethyl ether 2～7, salicylic acid 15～25.
The weight proportion of each active component of pharmaceutical composition of the present invention is:
Cajanin 98～102, Longistylin A 6～10, Longistylin C 2～4, pinostrobin 58～62, vitexin 58～62, naringenin dimethyl ether 2～7, salicylic acid 15～25.
Preferred weight part of each active component of pharmaceutical composition of the present invention is:
Cajanin 100, Longistylin A 8, Longistylin C 2, pinostrobin 60, vitexin 62, naringenin dimethyl ether 2, salicylic acid 20.
The conventional method that each active component of pharmaceutical composition of the present invention can adopt this area extraction from parts such as the whole plant of Semen Cajani or bark, leaf, flower, root, stem, separation, purification obtain.
A kind of preferred extracting method of each active component of pharmaceutical composition of the present invention comprises the following steps:
The whole plant of Semen Cajani or bark, leaf, flower, root, stem etc. are partly pulverized, torn up or smash to pieces, extract with the face of mistake 80% alcohol heating reflux, each 1 hour, ethanol extract is merged the back concentrating under reduced pressure get ethanol extract, handle filtration with hot water (60～70 ℃), get filtrate (A) and green sticking paste filtering residue (B).The A part is to get extract behind the ethyl acetate extraction, with this extract with the acetone agitation and filtration, it is Powdered that the gained filtering residue is khaki, be vitexin (crude product), the 20mL chloroform will be dissolved in behind the filtrate evaporate to dryness, and with 2% sodium hydroxide extraction, alkali extracting solution adds the hcl acidifying after-filtration, and filter cake is a salicylic acid.
The sticking paste B of green is added the thick silica gel of 200g chromatography mix thoroughly and dry, the porphyrize postposition is packed in the continuous extractor of 100g silica gel in advance, successively with petroleum ether (30-60 ℃ °) and the continuous eluting of dichloromethane, obtains C successively, D
1And D
2Three kinds of eluents.D
2The part have crystallization to separate out, with a small amount of cold dichloromethane agitation and filtration, the gained filter cake is cajanin, with behind the filtrate evaporate to dryness with D
1Merge, add the proper amount of acetone agitation and filtration, discard filter cake.Filtrate is with silica gel column chromatography, and with petroleum ether-dichloromethane (1: 9,1: 1) eluting, elder generation gets pinostrobin after getting Longistylin A.Reuse dichloromethane eluting silica gel post successively obtains E and F part, and F is partly added an amount of petroleum ether, places crystallize, filters, and the gained filter cake is Longistylin C, mother solution put into refrigerator a couple of days crystallize filter the naringenin dimethyl ether.
The chemical structural formula and the physicochemical property of each active component of pharmaceutical composition of the present invention are as follows:
Longistylin A cajanin Longistylin C
Pinostrobin vitexin naringenin dimethyl ether salicylic acid
Cajanin: C
21H
22O
4, white crystals, fusing point 176-178 ℃ (normal hexane-CH
2Cl
2), EIMS m/z338 " M "
+ 1H NMR (CDCl
3) δ: 1.73,1.79 (each 3H, s, C=C (CH
3)
2), 3.38 (2H, dJ=7Hz, ph-CH
2-3.97 (3H, s.OCH
3), 5.20 (1H, t, J=7Hz ,-CH-C-), 6.62 (1H, s, H-6), 6.80,7.82 (each 1H, d, J=16Hz ,-CH=CH-), 7.20-7.60 (B encircles H for 5H, m).
The acetylate of cajanin: fusing point 158-160 ℃, EIMS m/z 380[M]
+
Longistylin A: C
20H
22O
2The white needle, fusing point 76-78 ℃ (normal hexane-CH
2Cl
2);
EIMS m/z 294 " M "
+ 1HNMK (CDCl
3) δ: 1.76,1.83 (each 3H, s, C=C (CH
3)
2), 3.43 (2H, d J=7Hz, ph-CH
2-), 3.90 (3H, s.OCH
3), 5.28 (1H, t, J=7Hz, C=CH), 6.69 (2H, s ,-CH=CH), 7.08 (2H, s, H-2, H-6), 7.30-7.62 (B encircles H for 5H, m).
The acetylate of Longistylin A: 69～70 ℃ of fusing points;
1HNMR δ 2.32 (3H.s.OAc).
Longistylin C: C
20H
22O
2The white needle, fusing point 98-99 ℃ (normal hexane-CH
2Cl
2);
EIMS m/z 294 " M "
+ 1HNMK (CDCl
3) δ: 1.68,1.80 (each 3H, s, C=C (CH
3)
2), 3.43 (2H, d J=7Hz, ph-CH
2-), 3.80 (3H, s.OCH
3), 5.13 (1H, t, J=7Hz ,-CH=CH-), 6.40,6.71 (each 1H, d, J=2.5, H-4, H-6), 6.84,7.38 (each 1H, d, J=16Hz ,-CH=CH-), 7.21～7.58 (B encircles H for 5H, m).
The acetylate of Longistylin C: 60～62 ℃ of fusing points; EIMS m/z 336[M]
+ 1H NMR δ 2.34 (3H, s, OAc).
Pinostrobin: C
10H
14O
4The white platelet, fusing point 100-101 ℃ (methanol);
EIMS m/z 270 " M "
+ 1HNMK (CDCl
3) δ: 2.67-3.28 (2H, m, J
AB=17Hz, J
AX=11Hz, J
BX=5Hz, CH
2-3), 3.80 (3H, s, OCH
3), 5.43 (1H, dd, J
AX=11Hz, J
BX=5Hz, H-2), 6.08 (2H, s, H-6, H-8), 7.45 (B encircles H for 5H, s)
The pinostrobin acetylate, 150～152 ℃ of fusing points (methanol); EIMS m/z 312[M]
+
Male system is plain: C
21H
20O
10Yellow trickle prismatic crystal, fusing point 258-260 ℃ (water-pyridine);
EIMS m/z 414 " M-H
2O "
+ 1HNMR (DMSO-d
6) δ: 3.83 (6H, br, s, glucosyl group H), 4.65 (1H, d, J=8Hz, sugared end group H), 6.28 (1H, s.H-3), 6.79 (1H, s, H-6), and 6.90,8.03 (J=9Hz, B encircles H for each 2H, d), 10.40,10.88,13.20 (each 1H, s adds D
2O disappears, OH)
The full acetylated thing of vitexin, white crystals, 256～258 ℃ of fusing points (HAc-EtOH).
Salicylic acid: C
7H
6O
3, trickle white needle, 160 ℃ of fusing points, EIMS m/z 133[M]
+
Each active component behind the extraction purification is ground into fine powder,, promptly gets pharmaceutical composition of the present invention by described parts by weight mix homogeneously.Pharmaceutical composition of the present invention can use separately, also can be processed into different dosage forms with different excipient and use, as tablet, capsule, granule, oral liquid, tincture, aerosol, unguentum, drop pill, film preparation etc.Be preferably oral formulations.These excipient comprise diluent commonly used in the pharmaceutical technology, disintegrating agent, lubricant, binding agent, antioxidant etc.
Pharmaceutical composition of the present invention has the formation of the osteocyte of promotion and suppresses the osteocyte Absorption, thereby can effectively treat Woman climacteric (or oophorectomize), old people or drug-induced osteoporosis.In addition, pharmaceutical composition of the present invention also has antiinflammatory, exudation effect, can be used for the treatment of wound, burn and aphtha.Pharmaceutical composition of the present invention oral medicine once a day, effective dose are 50～150mg/kg.
Below by the specific embodiment beneficial effect of the present invention is described further, following embodiment only in order to the explanation the present invention, do not limit the scope of the invention.
The specific embodiment
1 in vitro tests of test example
With
3The H-thymus pyrimidine mixes method, the analogy osteoblast HOSTE85 of personnel selection and pharmaceutical composition effect of the present invention 48 hours, and medicine of the present invention as a result is 10 in concentration
-8The proliferation function that shows subject cell during g/mL relatively has notable difference, P＜0.05 with the blank group of not administration.
2 in vivo tests of test example
Adopt " the bone lesion test method(s) of suffering from a deficiency of the kidney ".Promptly extract and tried the female rats bilateral ovaries to cause osteoporosis rat be model (being divided into administration and not administration group), with femur bending strength (I), content of mineral substances (femur ash) (II) and uterus weight (II) be observation index, extract ovary administration after 8 days, dosage is 150,100,50 (mg/kg) once a day, gastric infusion is 28 days continuously, the result compares administration group (above-mentioned three kinds of dosage) and index I, II, the III of the matched group of administration all do not have significant difference, the P value of three dosage groups is respectively 0.001,0.01, demonstrate dose-effect relationship with 0.05.Histological examination, administration group sclerotin thickens, the trabecular bone showed increased.
Test example 3 antiinflammatory test
36 of white mice (are provided by Chinese Academy of Medical Sciences's animal center, about every body weight 25g) divide three groups, every group 12, be respectively administration group (I), positive controls (II) and blank group (III), mice overnight fasting (24 hours) back gastric infusion, I organizes to pharmaceutical composition 120mg/kg of the present invention (distilled water is made emulsion), II organizes to salicylic acid 118mg/kg, III organizes to the equivalent distilled water, each group all causes inflammation (every 0.05ml) with Oleum Tiglii after 1 hour, two ears about getting with corneal ring after 4 hours, weigh, statistical result shows, I group inflammation suppression ratio is 41.4%, the II group is 25.7%, with the III group notable difference is arranged relatively, the P value is respectively 0.01 and 0.05.
The test of test example 4 exudation
Male white mouse (20-22g), be divided into blank group (8), administration group (10), overnight fasting (24 hours) back gastric infusion (120mg/kg) at random, after 30 minutes by tail vein injection 2% indigo cigarette fat red (0.2ml/10g), instant lumbar injection 0.2ml/10g (0.41% acetic acid), 30 minutes pneumoretroperitoneum injection distilled water (2ml/10g), instant putting to death.Massage 40 times/, get ascites 1mL, adding trichloroacetic acid (0.1mL) is centrifugal, gets supernatant, to carry out colorimetric under the spectrophotometer 660nm wavelength.The result shows that the optical density of administration group and matched group have notable difference P＜0.05.
Each extraction of active ingredients of embodiment pharmaceutical composition of the present invention, separation, purification.
After Folium Cajani 1kg pulverizing, used face 80% alcohol heating reflux to extract, each 1 hour, the ethanol extract concentrating under reduced pressure of merging got ethanol extract 250g, handled with hot water (60～70 ℃) and filtered, and got the sticking paste filtering residue (B) of filtrate (A) and green.The A part gets the 9g extract with ethyl acetate extraction, this extract gets the Powdered vitexin of 310mg khaki (crude product) with the acetone agitation and filtration, is dissolved in the 20mL chloroform behind the filtrate evaporate to dryness, and with 2% sodium hydroxide extraction, alkali extracting solution adds the hcl acidifying after-filtration, gets the 100mg salicylic acid.
Green sticking paste B adds the thick silica gel of 200g chromatography and mixes thoroughly and dry, and the porphyrize postposition is packed in the continuous extractor of 100g silica gel in advance, successively with petroleum ether (30-60 °) and the continuous eluting of dichloromethane, obtains C (3g) successively, D
1(11g) and D
2(14g).
D
2The part have crystallization to separate out, with a small amount of cold dichloromethane agitation and filtration, cajanin (510mg), behind the filtrate evaporate to dryness with D
1Merge, add the proper amount of acetone agitation and filtration, discard filter cake.Filtrate gets Longistylin A (40mg) and pinostrobin (300mg) with silica gel column chromatography successively with petroleum ether-dichloromethane (1: 9,1: 1) eluting.Continuing gets E and F part with dichloromethane eluting silica gel post, and the latter adds an amount of petroleum ether, places crystallize, filter Longistylin C (12mg), mother solution put into refrigerator a couple of days crystallize filter naringenin dimethyl ether (13mg).
With each active component pulverize of the above-mentioned weight of gained, mix homogeneously promptly gets pharmaceutical composition of the present invention.Also can add different excipient, be processed into suitable dosage form by this area conventional method.
Claims (9)
1, a kind of pharmaceutical composition for the treatment of osteoporosis is characterized in that containing the active component of following weight proportion: cajanin 95～105, Longistylin A 3～13, Longistylin C 2～7, pinostrobin 55～65, vitexin 55～65, naringenin dimethyl ether 2～7, salicylic acid 15～25.
2, pharmaceutical composition according to claim 1, wherein the weight proportion of each component is: cajanin 98～102, Longistylin A 6～10, Longistylin C 2～4, pinostrobin 58～62, vitexin 58～62, naringenin dimethyl ether 2～7, salicylic acid 15～25.
3, pharmaceutical composition according to claim 1, wherein the weight proportion of each component is: cajanin 100, Longistylin A 8, Longistylin C 2, pinostrobin 60, vitexin 62, naringenin dimethyl ether 2, salicylic acid 20.
4,, can be processed into said dosage form on any pharmaceutics after it is characterized in that adding different excipient according to the pharmaceutical composition of claim 1,2 or 3 described treatment osteoporosis.
5, pharmaceutical composition according to claim 4, described pharmaceutical dosage form are oral formulations.
6, the purposes of the pharmaceutical composition in the claim 1,2 or 3 in preparation treatment osteoporosis agents.
7, the purposes of the pharmaceutical composition in the claim 1,2 or 3 in preparation treatment wound medicine.
8, the purposes of the pharmaceutical composition in the claim 1,2 or 3 in preparation treatment burn medicine.
9, the purposes of the pharmaceutical composition in the claim 1,2 or 3 in preparation treatment aphtha medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100084588A CN1294905C (en) | 2004-03-12 | 2004-03-12 | Drug composition for treating osteoporosis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100084588A CN1294905C (en) | 2004-03-12 | 2004-03-12 | Drug composition for treating osteoporosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1666745A true CN1666745A (en) | 2005-09-14 |
| CN1294905C CN1294905C (en) | 2007-01-17 |
Family
ID=35038128
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2004100084588A Expired - Fee Related CN1294905C (en) | 2004-03-12 | 2004-03-12 | Drug composition for treating osteoporosis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1294905C (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101172948B (en) * | 2007-11-01 | 2010-09-22 | 东北林业大学 | Method for separation and purification of cajanine and pinostrobin from extract of cajanus cajan branches and leaves |
| CN102387806A (en) * | 2009-04-10 | 2012-03-21 | 富士产业株式会社 | Process for production of orally ingestible composition containing arabinosyl vitexin, and use of the composition |
| CN103864742A (en) * | 2012-12-13 | 2014-06-18 | 天津科技大学 | Preparation and anti-tumor application of novel naringenin derivatives |
| CN107375261A (en) * | 2017-06-27 | 2017-11-24 | 东北林业大学 | Application of the pinostrobin in osteoporosis is prevented and treated |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1190716B1 (en) * | 1999-06-18 | 2004-05-19 | Hao Yuan | The leaves of cajanus cajan(l.) millsp and extract, formulation and uses thereof |
-
2004
- 2004-03-12 CN CNB2004100084588A patent/CN1294905C/en not_active Expired - Fee Related
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101172948B (en) * | 2007-11-01 | 2010-09-22 | 东北林业大学 | Method for separation and purification of cajanine and pinostrobin from extract of cajanus cajan branches and leaves |
| CN102387806A (en) * | 2009-04-10 | 2012-03-21 | 富士产业株式会社 | Process for production of orally ingestible composition containing arabinosyl vitexin, and use of the composition |
| CN103864742A (en) * | 2012-12-13 | 2014-06-18 | 天津科技大学 | Preparation and anti-tumor application of novel naringenin derivatives |
| CN107375261A (en) * | 2017-06-27 | 2017-11-24 | 东北林业大学 | Application of the pinostrobin in osteoporosis is prevented and treated |
| CN107375261B (en) * | 2017-06-27 | 2019-11-22 | 东北林业大学 | Application of the pinostrobin in prevention and treatment osteoporosis |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1294905C (en) | 2007-01-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1679058B1 (en) | Pharmaceutical composition for the treatment of cardiovascular and cerebrovascular diseases | |
| US8685469B2 (en) | In vitro anti-sickling activity of betulinic acid, oleanolic acid and their derivatives | |
| CH699749B1 (en) | Prepared mixture of spagyric and plants in propolis tincture for dry cough in children. | |
| SK194892A3 (en) | Method of production of diacetylreine | |
| CN1294905C (en) | Drug composition for treating osteoporosis | |
| KR100457970B1 (en) | Dendropanax morbifera Lev. extract, fraction and pharmaceutical composition containing thereof for recovering and proliferating effects on tibial tissue and periodontium ligamental tissue | |
| KR100733764B1 (en) | Composition comprising the cortex extract of albizzia julibrissin or kuraridinol isolated therefrom for preventing or treating hyperlipidemia | |
| KR101493877B1 (en) | pharmaceutical composition for preventing or treating bone diseases comprising spinasterol derivative sugar compound | |
| EP1846036A1 (en) | Reducing drug dependence or addiction | |
| CN105796764B (en) | Preparation method and application of negundo chastetree fruit total lignans | |
| FR2465484A1 (en) | Extract of e.g. eugenia jambolana lamarck - has antidiabetic, hypoglycaemic, hypolipaemic, weight reducing anorexic and anti-cataract activity | |
| EP0092226B1 (en) | Extract of plants of the family of hypoxidaceae for treatment of cancer | |
| KR102175269B1 (en) | A pharmaceutical composition comprising compounds isolated from Phlomoides umbrosa(Turcz.) Kamelin and Makhm for preventing or treating cancer | |
| CN108159204B (en) | Tibetan medicine composition with detoxifying and liver protecting effects | |
| KR20180054821A (en) | Triterpenoid-containing composition | |
| CS223879B2 (en) | Method of gaining natural terpenes with antipsoriatic effect | |
| KR20130059741A (en) | Pharmaceutical compositions for preventing or treating arthritis comprising euphorbia ebracteolata extracts | |
| KR100516560B1 (en) | Hypoglycemic and anagesic composition | |
| KR20240002573A (en) | Composition for improve, prevention or treatment of bone diseases containing an extracts or fractions of Rubus tozawae Nakai ex J.Y.Yang or compound derived from thereof | |
| KR20000019869A (en) | Composition comprising extract of seed of carthamus tinctorius l. for promoting regeneration of hard tissues | |
| JPH06211661A (en) | Antiinflammatory agent | |
| JPH0535131B2 (en) | ||
| KR100407557B1 (en) | Hard tissue regeneration accelerator composition comprising Eochocho extract | |
| KR100202757B1 (en) | Anti-diabetic composition | |
| KR20000019865A (en) | Composition comprising the extract of achyrantis radix for promoting the regeneration of hard tissues |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20070117 Termination date: 20160312 |